|
Market Closed -
NYSE
07:00:00 29/10/26 am AEDT
|
5-day change | 1st Jan Change | ||
| 1.040 USD | +0.97% |
|
+9.30% | -37.72% |
| 01/10 | EARNINGS: Generation Essentials interim profit jumps to USD28 million | AN |
| 07/08 | Lineage Cell Therapeutics, Inc., Q2 2026 Earnings Call, Aug 06, 2026 |
Company Valuation: Lineage Cell Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 413 | 198.9 | 190.7 | 110.8 | 404.7 | 263 | - | - |
| Change | - | -51.84% | -4.09% | -41.93% | 265.38% | -35.01% | - | - |
| Enterprise Value (EV) | 413 | 198.9 | 190.7 | 110.8 | 404.7 | 263 | 263 | 263 |
| Change | - | -51.84% | -4.09% | -41.93% | 265.38% | -35.01% | 0% | 0% |
| P/E | -9.42x | -7.8x | -9.08x | -5.58x | -5.96x | -17.3x | -8.1x | 32.8x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.2x | 0.5x | 0.2x | -0x | 0.2x | -0x | -0x |
| Capitalization / Revenue | 95.1x | 13.5x | 21.3x | 11.7x | 27.8x | 17.3x | 15.6x | 4.4x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 17.3x | 15.6x | 4.4x |
| EV / EBITDA | -0x | -0x | -0x | -0x | -0x | -7.82x | -8.94x | -8.58x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -8.29x | -7.47x | 40.1x |
| EV / FCF | - | 0x | -0x | -0x | -0x | -21.2x | -28.1x | 84.8x |
| FCF Yield | - | 0.32% | -15.3% | -21.4% | -4.8% | -4.71% | -3.55% | 1.18% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.26 | -0.15 | -0.12 | -0.09 | -0.28 | -0.06 | -0.1283 | 0.0317 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 4.341 | 14.7 | 8.945 | 9.499 | 14.56 | 15.19 | 16.83 | 59.72 |
| EBITDA 1 | -48.34 | -21.79 | -24.04 | -20.87 | -35.92 | -33.64 | -29.41 | -30.66 |
| EBIT 1 | -49.21 | -22.52 | -24.73 | -21.48 | -36.62 | -31.71 | -35.22 | 6.562 |
| Net income 1 | -43.02 | -26.27 | -21.49 | -18.61 | -63.53 | -22.64 | -34.44 | 8.605 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 2.450 | 1.170 | 1.090 | 0.502 | 1.670 | 1.040 | 1.040 | 1.040 |
| Nbr of stocks (in thousands) | 168,558 | 169,976 | 174,987 | 220,416 | 242,328 | 252,907 | - | - |
| Announcement Date | 10/3/22 | 9/3/23 | 7/3/24 | 10/3/25 | 5/3/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -17.33x | - | - | - | 263M | |
| 16.92x | 6.39x | 12.26x | 1.77% | 64.14B | |
| 30.57x | 8.11x | 26.59x | 0.05% | 55.53B | |
| 36.68x | 6.52x | 19.45x | 0.88% | 53.03B | |
| 35.39x | 3.41x | 14.74x | -.--% | 45.99B | |
| 49.25x | 5.68x | 31.09x | -.--% | 42.45B | |
| -19.59x | 189.6x | -20.86x | -.--% | 40.45B | |
| 31.7x | 8.06x | 20.96x | 0.41% | 32.25B | |
| 47.12x | 8.37x | 28.08x | -.--% | 34.47B | |
| 27.96x | 5.9x | 15.29x | -.--% | 24.23B | |
| Average | 23.87x | 26.89x | 16.40x | 0.34% | 39.28B | |
| Weighted average by Cap. | 27.93x | 25.38x | 16.46x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- LCTX Stock
- Valuation Lineage Cell Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
